Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

PathAI, a global leader in AI-powered pathology solutions, today announced it will present research from the outputs of ...

Zentalis Pharmaceuticals, Inc. announced that an abstract has been accepted for a poster presentation at the ... and capabilities to translate its science to advance research on additional areas ...

The poster presentations will include preclinical ... of precisely designed cancer therapeutics to transform what science can do for patients. Sutro’s fit-for-purpose technology, including ...

The poster will include clinical data as of an April 4, 2025 data cutoff from the Company's ongoing Phase 1/2 clinical trial evaluating azenosertib in combination with encorafenib and cetuximab in ...

Abstract and poster presentation details are below ... its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib ...

The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical ...

Matthew DeYoung Investor Relations and Media Argot Partners [email protected] Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology ...

OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, ...

SAN DIEGO and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today ...